Provided by Tiger Trade Technology Pte. Ltd.

Xencor

27.80
+0.80002.96%
Pre-market: 27.20-0.5975-2.15%04:11 EDT
Volume:753.11K
Turnover:20.90M
Market Cap:2.06B
PE:-12.77
High:28.16
Open:27.30
Low:27.07
Close:27.00
52wk High:28.16
52wk Low:7.71
Shares:74.13M
Float Shares:54.25M
Volume Ratio:0.54
T/O Rate:1.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1768
EPS(LYR):-1.2400
ROE:-29.07%
ROA:-16.83%
PB:4.10
PE(LYR):-22.42

Loading ...

Xencor Q2 EPS USD -0.29

Reuters
·
Aug 06

Xencor participates in a conference call with Cantor

TIPRANKS
·
Aug 04

Xencor’s XmAb412 Enters First-in-Human Testing: What Early-Stage Investors Should Watch

TIPRANKS
·
Aug 04

Xencor Expands Plamotamab Into Rheumatoid Arthritis: What Early Trial Progress Means for Investors

TIPRANKS
·
Aug 04

Xencor Shares Rise After Settlement Deal With Alexion

MT Newswires Live
·
Jul 31

Xencor Price Target Maintained with a $26.00/Share by Wedbush

Dow Jones
·
Jul 30

Xencor to receive $105M from Alexion to resolve Ultomiris royalty matter

TIPRANKS
·
Jul 30

Xencor Settles Ultomiris U.S. Royalty Dispute with Alexion for USD 105 Million

Reuters
·
Jul 30

Xencor - First $52.50 Mln Payment Expected August 2026; Second Payment Due One Year Later

THOMSON REUTERS
·
Jul 30

Xencor - to Continue Receiving Royalties on Ex-U.S. Ultomiris Sales

THOMSON REUTERS
·
Jul 30

Xencor to Receive $105 Million from Alexion to Resolve Ultomiris® U.S. Royalty Matter

THOMSON REUTERS
·
Jul 30

Wedbush Reaffirms Their Buy Rating on Xencor (XNCR)

TIPRANKS
·
Jul 22

Xencor Inc : Leerink Partners Assumes Coverage with Outperform Rating; Target Price $29

THOMSON REUTERS
·
Jul 22

Is Xencor (XNCR) Quietly Recasting Its Platform As A Solid-Tumor Oncology Story?

Simply Wall St.
·
Jul 19

Xencor's Cancer Drug Study Selected for Oral Presentation at ESMO; Shares Rise

MT Newswires Live
·
Jul 18

Xencor to Present Phase 1 Xmab819 Data in Advanced Kidney Cancer at ESMO 2026

Reuters
·
Jul 17

Xencor Announces Proffered Paper Oral Presentation at Esmo 2026 for Phase 1 Clinical Study of Xmab819 in Advanced Clear Cell Renal Cell Carcinoma

THOMSON REUTERS
·
Jul 17

Xencor (XNCR) Rebounds Sharply, Is It Still A Bargain?

Simply Wall St.
·
Jul 11

Xencor price target lowered to $27 from $29 at Truist

TIPRANKS
·
Jul 07

Xencor is Maintained at Buy by Truist Securities

Dow Jones
·
Jul 07